Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Androxal (enclomiphene citrate) Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women

NCT00413179
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Anovulation, Oligoovulation, Infertility, Hyperandrogenism
Interventions
Metformin, Clomiphene citrate, Placebo
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2003
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2006 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 3 Interventional

Treatment of Infertility in Women With Polycystic Ovary Syndrome

NCT00068861
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility, Pregnancy
Interventions
metformin XR, clomiphene citrate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women

NCT01340521
View directory record Official record
Conditions
Infertility
Interventions
Clomiphene Citrate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 1994
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 1, 2026, 8:03 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Androxal in Male Infertility

NCT02160704
View directory record Official record
Conditions
Infertility
Interventions
Enclomiphene citrate, Placebo
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 35 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation

NCT01291056
View directory record Official record
Conditions
Mood
Interventions
Placebo, Clomiphene
Other · Drug
Lead sponsor
University of Utah
Other
Eligibility
25 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Two Formulations of Androxal

NCT01984398
View directory record Official record
Conditions
Bioequivalence
Interventions
12.5 mg Androxal Formulation A, 12.5 mg Androxal Formulation B, 25 mg Androxal Formulation A, 25 mg Androxal Formulation B
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 1, 2026, 8:03 PM EDT
Not listed Phase 4 Interventional

Ovulation Induction With Clomiphene Citrate and Dexamethasone

NCT01856062
View directory record Official record
Conditions
Infertility
Interventions
Placebo, Dexamethasone
Drug
Lead sponsor
San Antonio Military Medical Center
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 1, 2026, 8:03 PM EDT
Not listed No phase listed Observational

Use of Clomiphene Citrate as an Inhibitor of Ovulation in an Oocyte Cryopreservation Cycle

NCT05866068
View directory record Official record
Conditions
Infertility, Female, Infertility
Interventions
Clomiphene
Drug
Lead sponsor
Neil Chappell
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
10 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

NCT01534208
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer

NCT03646162
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Veru-944, Placebo
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Glendale, Arizona • Los Angeles, California • San Bernardino, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH

NCT00296465
View directory record Official record
Conditions
InFertility
Interventions
Pulsatile gonadotropin-releasing hormone (GnRH), Clomiphene Citrate, Placebo Pulsatile GnRH, Placebo Clomiphene Citrate
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

NCT01923870
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

NCT01532414
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Mobile, Alabama • Little Rock, Arkansas • Garden Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

NCT02274181
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
19 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction

NCT00213148
View directory record Official record
Conditions
Anovulation
Interventions
Anastrozole 1 mg, Anastrozole 5 mg, Anastrozole 10 mg, Clomiphene Citrate 50 mg, Clomiphene Citrate 100 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 1, 2026, 8:03 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effect of Luteal Progesterone Support on Pregnancy Rates With Combined Clomid/ Gonadotropin & IUI

NCT02510534
View directory record Official record
Conditions
Pregnancy
Interventions
Menopur 150 international units, Endometrin 100 mg
Drug
Lead sponsor
Northwest Center for Infertility and Reproductive Endocrinology
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
520 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Margate, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993212
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg or 25 mg, AndroGel 1.62%, Placebo Capsules, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
8
States / cities
Jacksonville, Florida • Albany, New York • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 1, 2026, 8:03 PM EDT
Terminated Phase 2 Interventional Results available

Hypogonadism in Young Men With Type 2 Diabetes

NCT01155518
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Type 2 Diabetes
Interventions
testosterone, clomiphene, placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Not applicable Interventional Results available

Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit

NCT02294773
View directory record Official record
Conditions
Infertility
Interventions
Intrauterine Insemination, Clomiphene, Letrozole
Procedure · Drug
Lead sponsor
Midwest Fertility Specialists
Industry
Eligibility
21 Years to 39 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Fort Wayne, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

NCT01923857
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 1, 2026, 8:03 PM EDT
Active, not recruiting Phase 4 Interventional Results available

Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation

NCT05206448
View directory record Official record
Conditions
Polycystic Ovary Syndrome, PCOS, Infertility
Interventions
Letrozole, Clomiphene Citrate
Drug
Lead sponsor
Rachel Mejia
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Davenport, Iowa • Iowa City, Iowa • West Des Moines, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 1, 2026, 8:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficacy Study of the OV-Watch™ Personal Fertility Monitor for Women Using Clomiphene Citrate.

NCT00239603
View directory record Official record
Conditions
Infertility, Anovulation, Polycystic Ovary Syndrome
Interventions
OV-Watch
Device
Lead sponsor
Emory University
Other
Eligibility
21 Years to 42 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2007 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males

NCT01991327
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
Androxal, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 1, 2026, 8:03 PM EDT